Skip to main content
. Author manuscript; available in PMC: 2013 Apr 12.
Published in final edited form as: Nat Commun. 2011 Jul 5;2:380. doi: 10.1038/ncomms1386

Figure 2. The pharmacological profile of [125I]RHM-4 and sigma-2 receptor binding activity in PGRMC1 siRNA and cDNA treated HeLa cells.

Figure 2

a, Competitive binding studies of [125I]RHM-4 were carried out with the PGRMC1 ligand AG-205, sigma-2 receptor ligands DTG, WC-26, SV119, and siramesine or with the sigma-1 receptor ligand (+)-pentazocine. [125I]RHM-4 binding was blocked by AG-205 and the sigma-2 ligands but not by (+)-pentazocine. n = 2, sample in triplicate. b, Typical western blot confirming PGRMC1 protein expression knockdown in PGRMC1 specific siRNA treated HeLa cells relative to nontargeting siRNA treated controls compared to actin (loading control). c, The bar graph shows reduced sigma-2 receptor binding activity in the PGRMC1 knockdown cells; * p<0.01, Student's t-test, n=3. d, Typical western blot confirming increased PGRMC1 protein expression in PGRMC1 transfected HeLa cells relative to vector transfected controls. e, Bar graph showing increased sigma-2 receptor binding activity in PGRMC1 transfected cells; * p<0.01, Student's t-test, n=3. Error bars in a, c, d represent SEM.